Alexion's Soliris Adds Prescriber Certification In Move From RiskMAP To REMS
The REMS for the hemolysis drug seems to be more onerous than the previous RiskMAP, although the company says there are no new safety problems behind the change.
The REMS for the hemolysis drug seems to be more onerous than the previous RiskMAP, although the company says there are no new safety problems behind the change.